Novel Long-Acting Ropeginterferon Alfa-2b: Pharmacokinetics, Pharmacodynamics, and Safety in a Phase I Clinical Trial.
Sign Up to like & getrecommendations! Published in 2021 at "British journal of clinical pharmacology"
DOI: 10.1111/bcp.15176
Abstract: AIM Ropeginterferon alfa-2b is a novel, long-acting pegylated interferon alfa-2b. We aimed to evaluate its safety, pharmacokinetics (PK) and pharmacodynamics (PD). METHODS Thirty-six subjects received single subcutaneous injection of ropeginterferon alfa-2b at doses ranging 24-270… read more here.
Keywords: safety; pegylated ifn; ropeginterferon alfa; ifn alfa ... See more keywords